Norgine BV - Strategic SWOT Analysis Review

December 2020 | 30 pages | ID: NC92F5AD4706EN
GlobalData

Abstracts

Norgine BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Norgine BV (Norgine) develops, manufactures, and commercializes specialty pharmaceuticals and medical devices. The company's product portfolio spans branded drugs and devices in the areas of gastroenterology, hepatology, and cancer and supportive care. It also advances pipeline candidates for the treatment of various gastroenterological and hepatological diseases and disorders. Norgine serves healthcare systems and patients in Europe, New Zealand, and Australia. Its prominent partners include Takeda, Bausch Health, Abeona Therapeutics, Alfasigma, Amicus, China Medical System Holdings, Modi-Mundipharma, Navidea, Noventure, and Olympus Corp, among others. The company has subsidiaries in the UK, Italy, Germany, Portugal, Switzerland, Austria, France, Belgium, Denmark, Spain, New Zealand, Australia, South Africa, and Egypt. Norgine is headquartered in the Netherlands.

Norgine BV Key Recent Developments

Jun 16,2020: Norgine senior management changes: Christopher Bath appointed Chief Operating Officer
Jun 19,2019: Norgine recognised for excellence in health and safety with RoSPA Gold Medal Award fifth year in a row
Apr 04,2019: Norgine: New study highlights need to increase public understanding of important role of colonoscopy in preventing and diagnosing gastrointestinal diseases, including Colorectal Cancer

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

Contents

Table of Contents
List of Tables
List of Figures

SECTION 1 - ABOUT THE COMPANY

Norgine BV - Key Facts
Norgine BV - Key Employees
Norgine BV - Key Employee Biographies
Norgine BV - Major Products and Services
Norgine BV - History
Norgine BV - Company Statement
Norgine BV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Norgine BV - Business Description
Business Segment: Net Product Revenue
Performance
R&D Overview
Norgine BV - Corporate Strategy
Norgine BV - SWOT Analysis
SWOT Analysis - Overview
Norgine BV - Strengths
Norgine BV - Weaknesses
Norgine BV - Opportunities
Norgine BV - Threats
Norgine BV - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Norgine BV, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Norgine BV, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Jun 16, 2020: Norgine senior management changes: Christopher Bath appointed Chief Operating Officer
Jun 19, 2019: Norgine recognised for excellence in health and safety with RoSPA Gold Medal Award fifth year in a row
Apr 04, 2019: Norgine: New study highlights need to increase public understanding of important role of colonoscopy in preventing and diagnosing gastrointestinal diseases, including Colorectal Cancer

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Norgine BV, Key Facts
Norgine BV, Key Employees
Norgine BV, Key Employee Biographies
Norgine BV, Major Products and Services
Norgine BV, History
Norgine BV, Subsidiaries
Norgine BV, Key Competitors
Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Norgine BV, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Norgine BV, Recent Deals Summary

List Of Figures

LIST OF FIGURES

Norgine BV, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Norgine BV, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

ALTANA Pharma AG
Apotex Nederland BV
Aptalis Pharmatech Inc
Centrient Pharmaceuticals Netherlands BV
Enceladus Pharmaceuticals BV
Ferring International Center SA
Janssen-Cilag BV
Protalix BioTherapeutics Inc
Raptor Pharmaceuticals Europe BV
RedHill Biopharma Ltd
Riemser Pharma GmbH
Stada Arzneimittel AG
Synergy Pharmaceuticals Inc
Therabel International Services SA/NV
Theravance Biopharma Inc